Chapter category:
TRAIL and other TRAIL Receptor Agonists as Novel Cancer Therapeutics
Therapeutic Targets
of the TNF Superfamily
Edited by: Iqbal S. GrewalISBN: TBA
» Get more information about this book at landesbioscience.com «
Chapter authors:
Christina Falschlehner, Tom M. Ganten, Ronald Koschny, Uta Schaefer and Henning Walczak
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), also known as Apo2L, is a member of the TNF superfamily (TNFSF) of cytokines. TRAIL gained much attention during the past decade due to the demonstration of its therapeutic potential as a tumor-specific apoptosis inducer. TRAIL was identified as a protein with high homology to other members of the TNF cytokine family, especially to the ligand of Fas/Apo-1 (CD95), CD95L (FasL/APO-1L). TRAIL has been shown to induce apoptosis selectively in many tumor cell lines without affecting normal cells and tissues, making TRAIL itself as well as agonists of the two human receptors of TRAIL which can submit an apoptotic signal, TRAIL-R1 (DR4) and TRAIL-R2 (DR5), promising novel biotherapeutics for cancer therapy. An increasing number of publications now shows that TRAIL resistance in primary human tumor cells will have to be overcome and that sensitization to TRAIL-induced apoptosis will be required in many cases. Therefore, it will also be instrumental to develop suitable diagnostic tests to identify patients who will benefit from TRAIL-based novel anticancer therapeutics and those who will not. Interestingly, the first clinical results even in monotherapy with TRAIL as well as various agonistic TRAIL receptor-specific antibodies have shown encouraging results. This chapter provides a compact overview on the biochemistry of the TRAIL/TRAIL-R system, the physiological role of TRAIL and its receptors and the results of clinical trials with TRAIL and various TRAIL-R agonistic antibodies.
Christina Falschlehner
Tom M. Ganten
Ronald Koschny
Uta Schaefer
Henning Walczak
Div. of Apoptosis Regulation (D040), Tumor Immunology Program, German Cancer Research Center (DKFZ), Heidelberg, Germany
Additional chapters from this book:
RANK(L) as a Key Target for Controlling Bone Loss
Andreas Leibbrandt and Josef M. Penninger
Bone‑related diseases, such as osteoporosis or rheumatoid arthritis, affect hundreds of millions of people worldwide and pose a tremendous burden to health care. By deepening our understanding o...
GITR: A Modulator of Immune Response and Inflammation
Giuseppe Nocentini and Carlo Riccardi
Glucocorticoid‑Induced TNFR‑Related (GITR) protein belongs to Tumor Necrosis Factor Receptor Superfamily (TNFRSF) and stimulates both the acquired and innate immunity. It is expressed in s...
Tumor Necrosis Factor Receptor Superfamily Member 21: TNFR‑Related Death Receptor 6, DR6
Robert Benschop, Tao Wei and Songqing Na
TNFRSF21 (death receptor‑6, DR6) is an orphan TNF receptor superfamily member and belongs to a subgroup of receptors called death receptors. DR6 is expressed ubiquitously with high expression in...
Targeting CD30/CD30L in Oncology, Autoimmune and Inflammatory Diseases
Ezogelin Oflazoglu, Iqbal S. Grewal and Hanspeter Gerber
The transmembrane receptor CD30 (TNFRSF8) and its ligand CD30L (CD153, TNFSF8) are members of the tumor necrosis factor (TNF) superfamily and display restricted expression in subpopulations of activat...
4‑1BB as a Therapeutic Target for Human Disease
Seung-Woo Lee and Michael Croft
4‑1BB (CD137) is being thought of as an attractive target for immunotherapy of many human immune diseases based on encouraging results with 4‑1BB agonistic antibody treatment in mouse mode...
Targeting TNF for Treatment of Cancer and Autoimmunity
Gautam Sethi, Bokyung Sung, Ajaikumar B. Kunnumakkara and Bharat B. Aggarwal
Tumor necrosis factor‑α (TNF‑α) was first isolated two decades ago as a macrophage‑produced protein that can effectively kill tumor cells. TNF‑α is also an essen...
OX40 (CD134) and OX40L
Michael J. Gough and Andrew D. Weinberg
The interaction between OX40 and OX40L plays an important role in antigen‑specific T‑cell expansion and survival. While OX40 is expressed predominantly on T-lymphocytes early after antigen...
Targeting the LIGHT-HVEM Pathway
Carl F. Ware
Tumor necrosis factor (TNF)-related cytokines function as key communication systems between cells of the immune system and mediate inflammation and tissue destruction. LIGHT (TNFSF14) is a key compone...
TRAIL and other TRAIL Receptor Agonists as Novel Cancer Therapeutics
Christina Falschlehner, Tom M. Ganten, Ronald Koschny, Uta Schaefer and Henning Walczak
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), also known as Apo2L, is a member of the TNF superfamily (TNFSF) of cytokines. TRAIL gained much attention during the past decade ...
Therapeutic Potential of VEGI/TL1A in Autoimmunity and Cancer
Gautam Sethi, Bokyung Sung and Bharat B. Aggarwal
Vascular endothelial growth inhibitor (VEGI, TNFSF‑15) is a novel member of the tumor necrosis factor (TNF) superfamily that consists of 174 amino acids and exhibits a 20% to 30% sequence homolo...
Targeting of BAFF and APRIL for Autoimmunity and Oncology
Maureen C. Ryan and Iqbal S. Grewal
BLyS and APRIL are tumor necrosis factor superfamily members shown to be important for B‑cell development, maturation and survival. Recent data also indicate that these cytokines regulate the su...
Therapeutic Interventions Targeting CD40L (CD154) and CD40:The Opportunities and Challenges
Che-Leung Law and Iqbal S. Grewal
CD40 was originally identified as a receptor on B-cells that delivers contact‑dependent T helper signals to B-cells through interaction with CD40 ligand (CD40L, CD154). The pivotal role played b...
The role of FasL and Fas in Health and Disease
Martin Ehrenschwender and Harald Wajant
The FS7‑associated cell surface antigen (Fas, also named CD95, APO‑1 or TNFRSF6) attracted considerable interest in the field of apoptosis research since its discovery in 1989. The groups ...
